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Abstract
Background—The role of comorbidities in survival of breast cancer patients has not been well 
studied, particularly in non-white populations.
Methods—We investigated the association of specific comorbidities with mortality in a 
multiethnic cohort of 8,952 breast cancer cases within the California Breast Cancer Survivorship 
Consortium (CBCSC), which pooled questionnaire and cancer registry data from five California-
based studies. In total, 2,187 deaths (1,122 from breast cancer) were observed through December 
31, 2010. Using multivariable Cox proportional hazards regression, we estimated hazards ratios 
(HR) and 95% confidence intervals (CI) for overall and breast cancer-specific mortality associated 
with previous cancer, diabetes, high blood pressure (HBP), and myocardial infarction (MI).
Results—Risk of breast cancer-specific mortality increased among breast cancer cases with a 
history of diabetes (HR=1.48, 95% CI=1.18, 1.87) or MI (HR=1.94, 95% CI=1.27–2.97). Risk 
patterns were similar across race/ethnicity (non-Latina White, Latina, African American and Asian 
American), body size, menopausal status, and stage at diagnosis. In subgroup analyses, risk of 
breast cancer-specific mortality was significantly elevated among cases with diabetes who 
received neither radiation nor chemotherapy (HR=2.11, 95% CI=1.32–3.36); no increased risk was 
observed among those who received both treatments (HR=1.13, 95% CI= 0.70–1.84) (P 
interaction= 0.03). A similar pattern was found for MI by radiation and chemotherapy (P 
interaction=0.09).
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Conclusion—These results may inform future treatment guidelines for breast cancer patients 
with a history of diabetes or MI.
Impact—Given the growing number of breast cancer survivors worldwide, we need to better 
understand how comorbidities may adversely affect treatment decisions and ultimately outcome.
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Introduction
The presence of chronic illnesses or comorbidities at the time of breast cancer diagnosis is 
common. In an analysis based on Medicare claims data, 42% of breast cancer patients had 
one or more comorbidities near the time of diagnosis (1), and breast cancer patients with one 
or more comorbid conditions have been shown to experience significantly worse survival 
(2). The current evidence, however, has some limitations, including the use of summary 
indices such as the Charlson Comorbidity Index which does not consider the influence of 
individual comorbidities on prognosis, the focus on overall mortality only, and the lack of 
information on lifestyle-related factors that could modify the observed associations.
Specific comorbidities may account for some of the racial/ethnic survival differences after 
breast cancer diagnosis; however, most prior studies have been limited by relatively small 
sample sizes and lack of information on some racial/ethnic groups (Asian Americans, 
Latinas). The prevalence of hypertension (3, 4) and diabetes (3) is higher in African 
American than White breast cancer patients and associations have been reported between 
these comorbidities and overall mortality (3) and between hypertension and breast cancer-
specific mortality (4).
To better understand the association of specific comorbidities with overall mortality and 
breast cancer-specific mortality by race/ethnicity, we analyzed data from the California 
Breast Cancer Survivorship Consortium (CBCSC) (5). We considered duration and 
treatment of comorbidities, as well as stage at diagnosis and treatment for breast cancer, to 
explore reasons for the potential adverse effects of comorbidities on survival.
Materials and Methods
The California Breast Cancer Survivorship Consortium (CBCSC)
This analysis included five studies from the CBCSC, which was established in 2011 to better 
understand racial/ethnic disparities in survival (5). They include three population-based 
case-control studies of breast cancer [the Asian American Breast Cancer Study (AABCS) 
(6); the Women’s Contraceptive and Reproductive Experiences study (CARE) (7); and the 
San Francisco Bay Area Breast Cancer Study (SFBCS) (8)], one breast cancer survivor 
cohort [the Life after Cancer Epidemiology (LACE) Study (9)], and one cohort study [the 
California Teachers Study (CTS) (10)]. The CTS cohort identified newly diagnosed breast 
cancer cases through annual linkages with the California Cancer Registry (CCR). The 
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CBCSC harmonized and pooled questionnaire data from the individual studies and 
assembled uniform CCR data on clinical characteristics and mortality. The study was 
approved by the institutional review boards of all participating institutions and the California 
State Committee for the Protection of Human Subjects.
Comorbidity variables, covariates, and clinicopathologic factors
We obtained patient information on comorbid conditions [diabetes, high blood pressure 
(HBP) or hypertension, myocardial infarction (MI) or heart attack] from questionnaires. 
Questions on comorbidities were similar in the three case-control studies, which conducted 
in-person interviews on average 3–18 months after breast cancer diagnosis thatqueried for 
physician diagnoses that occurred before diagnosis, the age when first diagnosed and 
treatment for the condition. In AABCS and CARE, questions on diabetes, HBP and MI were 
asked. In SFBCS, questions on diabetes and HBP were added later and the information is 
available on 41% of patients. In the CTS, participants completed self-administered 
questionnaires before breast cancer diagnosis which asked about diabetes, MI, and HBP at 
the time of study enrollment. Conditions that were diagnosed after the completion of the 
baseline questionnaires were not captured. CTS participants were asked to check ‘yes’ if 
they had the condition but were not asked when they were diagnosed with the condition. In 
LACE, participants were asked if they were ever told by a doctor or other health 
professional of having diabetes, HBP, or MI and when they were first told. Only conditions 
that occurred prior to the date of breast cancer diagnosis were considered.
CBCSC participants were linked to the CCR (5) to obtain information on previous cancer 
(excluding non-melanoma skin cancer), AJCC stage, estrogen receptor (ER) and 
progesterone receptor (PR) status, nodal positivity, grade, tumor size, surgery type, 
chemotherapy, hormonal therapy, radiation therapy, marital status, and block-group 
composite measure of socioeconomic status (SES) of residence at diagnosis (11).
Statistical Analysis
Cox proportional hazards regression models with attained age as the time scale and study as 
a stratification variable were used to estimate adjusted hazard ratios (HRs) and 95% 
confidence intervals (CIs) in overall and race/ethnicity-specific models (5). The entry date 
was the date of diagnosis for women in the CTS or the date of interview for the case-control 
studies and LACE. The exit date was the date of death or end of follow-up (December 31, 
2010), whichever occurred first. Analytic endpoints included overall and breast cancer-
specific mortality. Deaths from breast cancer were identified from underlying causes of 
death on the death certificate based on International Classification of Diseases, Ninth 
Revision, codes 174–175 or International Classification of Diseases, Tenth Revision, code 
C50.
Multivariable analyses adjusted for age at diagnosis, race/ethnicity, education, neighborhood 
SES, nativity (U.S. or foreign born), age at first birth, smoking status, alcohol consumption, 
body mass index (BMI), marital status, AJCC stage, grade, tumor size, nodal involvement, 
surgery type, ER/PR status, chemotherapy, and radiation. Of the 10,212 breast cancer 
patients available for this analysis, information on comorbidities other than previous cancer 
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was available for patient subsets (8,946 for diabetes, 8,952 for HBP, and 8,108 for MI). We 
conducted analyses mutually adjusted for previous cancer, diabetes, HBP, and MI based on 
8,108 patients when we considered all four conditions simultaneously. We considered 
severity of comorbidity based on self-reported duration of comorbidity and whether 
treatment was received for the comorbidity. We evaluated effect modification in the 
associations between comorbidity (diabetes, HBP, MI) and mortality outcomes by 
menopausal status, BMI, and AJCC stage and by first course of breast cancer treatment 
(type of breast surgery, radiation and chemotherapy treatment) as recorded in the CCR. We 
also examined the effect of comorbidities in patients with and without previous cancer. 
Statistical significance of multiplicative interaction terms was estimated with the Wald test 
by including a cross-product term of the exposure and the potential effect modifier in the 
Cox models.
Results
Table 1 shows the prevalence and characteristics of breast cancer patients with each type of 
comorbidity. The prevalence of HBP was high (27.7%), followed by previous cancer 
(6.8%), diabetes (5.5%), and MI (1.7%). There were significant differences in the 
prevalence of all four conditions by age and race/ethnicity. Patients with these comorbidities 
were less likely to have received chemotherapy or radiation therapy.
History of previous cancer, diabetes, HBP and MI were associated with a significantly 
increased risk of overall mortality after adjustment for tumor characteristics and lifestyle 
factors (Table 2); results were similar after further adjustment for other comorbidities. The 
increased risk of breast cancer-specific mortality among patients with diabetes (HR=1.48, 
95% CI=1.18–1.87) and MI (HR=1.94, 95% CI=1.27–2.97) remained when we mutually 
adjusted for the other comorbidity and covariates, but the increased risk in relation to 
previous cancer was not statistically significant. HPB was not associated with breast cancer-
specific mortality (Table 2).
Evaluating the comorbidity-mortality associations within the four major racial/ethnic groups 
(Table 2) shows that previous cancer was associated with overall mortality in Latinas and 
Asian Americans, but with breast cancer-specific mortality only among Latinas (HR=3.20, 
95% CI= 1.37–7.46). Diabetes was associated with increased overall mortality (HRs ranged 
from 1.54 to 3.04; all P’s <0.05) and suggestive for breast cancer-specific mortality across 
all four groups, with the latter only statistically significant in non-Latina Whites (HR=1.63, 
95% CI=1.10–2.43). HBP was associated with overall mortality in non-Latina Whites but 
not with breast cancer-specific mortality. In Asian Americans, HBP was associated with 
lower risk of breast cancer-specific mortality; this finding differed significantly from that in 
non-Latina Whites (P interaction=0.01). History of MI was associated with overall 
(HR=1.44, 95% CI=1.06–1.95) and breast cancer-specific (HR=1.82, 95% CI=1.04–3.16) 
mortality in non-Latina Whites; non-significant positive associations were found in African 
Americans and Asian Americans (Table 2).
Duration of and treatment for diabetes appeared to influence mortality (Table 3). Risk of 
breast cancer-specific mortality increased with increasing duration of diabetes. Ppatients 
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with a history of diabetes preceding breast cancer diagnosis by ≥15 years showed highest 
breast cancer-specific mortality (HR=1.81, 95% CI=1.17–2.81), the risk was intermediate 
among patients who had diabetes for 6–14 years (HR=1.45, 95% CI=0.92–2.27), and lowest 
among those who had diabetes for ≤5 years prior to breast cancer diagnosis (HR=1.13, 95% 
CI=0.76–1.69) compared to those without diabetes. Breast cancer patients, who reported 
treatment for diabetes did not show increased risk of breast cancer-specific mortality, 
whereas a significant 2-fold increased risk was observed among those who reported no 
treatment for diabetes (HR=2.12, 95% CI=1.25–3.63) or were unknown for treatment 
(HR=2.02, 95% CI=1.39–2.93). Similarly, there was a pattern of increasing risk of overall 
and breast cancer-specific mortality with longer duration since MI.
We also examined the combined effects of previous cancer and other comorbidities on 
mortality (Table 3). Women with a history of diabetes but no previous cancer showed 
significant increased risks of overall (HR=1.77) and breast cancer-specific (HR=1.46) 
mortality; those who had both diabetes and previous cancer had even higher overall 
(HR=3.02) and breast cancer-specific (HR=2.10) mortality. Similarly, patients with a history 
of MI, but no previous cancer had significantly elevated overall (HR=1.48) and breast 
cancer-specific (HR=1.86) mortality. Overall mortality was more than 3-fold higher among 
those with both previous cancer and MI (HR=3.33), but for breast cancer-specific mortality, 
the increased risk was not statistically significant. Overall mortality was significantly 
increased for those with HBP but no previous cancer (HR=1.18) as well as for those with 
HBP and previous cancer (HR=1.67) but there were no significant associations with breast 
cancer-specific mortality.
History of HBP was not associated with breast cancer-specific mortality irrespective of stage 
of breast cancer diagnosis (data not shown). In contrast, breast cancer patients with early 
(stage I or II) or more advanced (stage III or IV) breast cancer and a history of diabetes 
showed elevated risk of breast cancer-specific mortality; the respective HRs were 1.49 (95% 
CI=1.14, 1.95), and 1.99 (1.24–3.19) (data not shown). Patients with early stage (I or II) 
breast cancer and history of MI had a significant increased risk of breast cancer-specific 
mortality (HR=1.90, 95% CI=1.19–3.04); the increased risk among those with stage III/IV 
and MI was not statistically significant (HR=1.79, 95% CI=0.64–4.96). The mortality 
patterns associated with diabetes, HBP, and MI were similar by menopausal status and by 
BMI category (data not shown).
We investigated whether the association between comorbidities and mortality differed by 
breast cancer treatment (surgery, radiation, chemotherapy). The mortality patterns associated 
with MI or previous cancer did not differ between those who had a mastectomy or breast 
conserving surgery (Table 4). Among patients with diabetes, the risk of overall mortality 
was significantly elevated irrespective of surgery type whereas breast cancer-specific 
mortality was increased among those who had a mastectomy (HR=1.60, 95% CI=1.17–
2.18), but not among those who had breast conserving surgery (HR=1.07, 95% CI=0.71–
1.61) (P interaction =0.10). In contrast, an increased risk of overall mortality associated with 
HBP was observed among those who had breast-conserving surgery, but not among those 
who had a mastectomy (P interaction=0.02); the results for breast cancer-specific mortality 
were comparable (Table 4).
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Risk of breast cancer-specific mortality was highest among patients with a history of 
diabetes who had received neither radiation nor chemotherapy (HR=2.11, 95% CI=1.32–
3,36) (P interaction=0.03), intermediate among those who received either treatment 
(HR=1.49, 95% CI=1.05–2.11) (P interaction=0.47) and lowest among those who received 
both treatments (HR=1.13, 95% CI=0.70–1.84) when compared to breast cancer patients 
who had no diabetes with corresponding treatments (Table 5). A similar pattern of results 
was observed for diabetes and overall mortality when treatment with radiation and 
chemotherapy was considered. There were no increased risks of overall or breast cancer-
specific mortality in association with history of MI for those treated with both chemotherapy 
and radiation. However, patients with MI, who received either radiation or chemotherapy, or 
neither treatment showed significantly elevated risks of breast cancer-specific mortality (HR 
= 2.45 and 2.40, respectively) and overall mortality (HR = 1.95 and 1.64, respectively) 
(Table 5).
Discussion
In this large, multiethnic study of breast cancer patients followed an average of 9.8 ± 3.5 
years, patients with a history of diabetes or MI had 1.5- and 1.9-fold greater risk, 
respectively, of breast cancer-specific mortality than patients without these comorbidities 
after adjustment for other comorbidities, tumor characteristics and lifestyle factors. These 
results were similar across racial/ethnic groups, BMI categories, menopausal status and 
stage of breast cancer at diagnosis. However, higher risk of breast cancer-specific mortality 
appeared to be confined to patients not treated with radiation or chemotherapy. The 
association was strongest for patients who reported no treatment for diabetes. Our findings 
on previous cancer in combination with diabetes and MI suggest synergistic effects of these 
conditions. These results emphasize that the survival of breast cancer patients may be 
compromised because of under-treatment for a specific comorbidity or for their breast 
cancer.
Diabetes is characterized by high levels of growth factors and inflammatory markers (12) 
which have been associated with carcinogenesis and adverse impact on breast cancer 
outcomes (13). Both cancer registry-based (1, 3, 14–17) and non-registry based (18, 19) 
studies reported higher risk of overall mortality in diabetic breast cancer patients. Few 
studies have investigated the effects of diabetes on breast cancer-specific mortality; 
increased mortality was reported in two studies (18, 20), but not in a third study which also 
adjusted for BMI and other lifestyle factors (19). Our results strengthen the evidence that 
diabetes is associated with breast cancer-specific mortality. We were able to adjust for 
lifestyle factors, BMI, clinical and pathologic factors as well as other comorbidities, and 
observed similar findings across racial/ethnic groups.
Our results on breast cancer-specific mortality and diabetes were strongest for patients with 
a long (≥15 year) history of diabetes, who reported no treatment for diabetes, had a history 
of previous cancer, or had neither chemotherapy nor radiation treatment. The longer 
presence of diabetes or untreated diabetes may be associated with hyperinsulinemia related 
to underlying insulin resistance which may stimulate tumor growth (12). Although we do 
not have information on reasons for the lack of treatment for diabetes, it is plausible that 
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patients who were treated for their diabetes may have fewer or less severe sequelae of 
diabetes, whereas those with a long history or uncontrolled diabetes may be more 
compromised, resulting in higher risk of end-organ symptoms (i.e, neuropathy, kidney 
failure), reducing their options for full-dose, effective breast cancer treatment. Patients with 
previous cancer may have already received lifetime maximum doses of specific 
chemotherapy, which may further reduce treatment options for their breast cancer. Patients 
who were treated with chemotherapy or radiation may be healthier than their counterparts 
who were not offered comparable therapy. Radiation, chemotherapy, and other treatments 
are also less likely to be offered to breast cancer patients with comorbidities, and treatment 
intensity and patient compliance may be lower (21–25). Thus our findings are consistent 
with studies which showed worse survival in the absence of radiotherapy and chemotherapy 
(16, 24, 26–28).
CBCSC breast cancer patients with a history of MI experienced increased overall and breast 
cancer-specific mortality irrespective of a prior cancer, but risks were higher among those 
who did not receive radiation or chemotherapy. Breast cancer patients with a history of 
cardio-vascular disease experienced elevated overall mortality in two cancer registry-based 
studies (1, 16) and elevated breast cancer-specific mortality in another study (20), but not in 
two smaller, non-cancer registry-based studies (18, 19). As noted above, the omission of 
radiotherapy may have adverse effects on recurrence rates and overall mortality (28–30). 
The lower receipt of chemotherapy among women with MI may be related to concern that 
specific chemotherapy such as anthracyclines may have long-term cardiac toxicity in breast 
cancer patients, particularly in older patients (31–33).
Our finding of an association of HBP with overall but not breast cancer-specific mortality is 
similar to the finding in the WHEL study (18). The reasons for the weaker associations with 
HBP in our study compared to two previous studies (3, 4) may be explained, in part, by 
smoking, alcohol consumption, and other factors that were not considered in previous 
studies. CBCSC Asian American women with HBP showed lower overall and breast cancer-
specific mortality. These results are similar to those reported in Shanghai Chinese (19) and a 
study of mostly Whites (17). Interestingly, the HBP-overall mortality association was 
stronger among women who had breast conserving surgery (Table 4) and among patients 
who had either or neither radiation and chemotherapy treatment (Table 5). Treatment for 
breast cancer as well as medications used to treat HBP (i.e., beta-blockers) may influence 
breast cancer survival (34); thus it will be important to include treatment information in 
future investigations.
Strengths of this study include the largest sample size to date to examine the impact of 
several common comorbidities on the risk of overall and breast cancer-specific mortality 
among racially and ethnically diverse breast cancer patients. We were able to adjust for most 
known prognostic and treatment-related factors as well as important lifestyle factors. In 
addition, we had information on age at diagnosis of the comorbidity and receipt of treatment 
for the specific comorbidity. Sensitivity analyses restricted to the three case-control studies 
which asked very similar questions on comorbidities confirmed the overall and breast 
cancer-specific mortality associations with the four comorbidities (data not shown). 
Limitations include availability of a small group of comorbidities and information on 
Wu et al. Page 7













comorbidities (except previous cancer) based entirely on self-report. Better understanding of 
overall and breast-cancer specific mortality in relation to the individual comorbidities, as 
well as a combination of comorbidities such as the Charlson Comorbidity Index, diagnosed 
before as well as after (35–37) breast cancer diagnosis, will be needed. Our cancer registry 
information on radiation and chemotherapy for breast cancer was limited to the first course 
of treatment. While we had some information on treatment for the comorbidities, this was 
crude and lacked details such as specific diabetic medications or the reasons why some 
patients were not treated. Collection of information on specific diabetic medications (e.g., 
metformin, sulfonylurea) will help inform the extent to which specific treatments may 
influence outcomes in breast cancer patients (38, 39), a topic of immense interest.
In summary, we found that the risk of breast cancer-specific mortality was significantly 
increased among women with a history of diabetes or MI. Stratified analyses showed that 
risk patterns for diabetes and MI varied significantly by receipt of radiation and 
chemotherapy and that risk was higher among patients with a previous cancer. With the 
growing number of breast cancer survivors worldwide, confirmation of these results is 
needed in order to better understand how comorbidities may adversely affect treatment 
decisions and ultimately outcome.
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